8-K: Biotricity Amends Series B Preferred Stock Terms, Eliminating Voting Rights

Biotricity Inc. has amended the terms of its Series B Convertible Preferred Stock, removing voting rights previously granted to holders.

Summary

• Biotricity Inc. filed an amendment to the Certificate of Designations for its Series B Convertible Preferred Stock on April 1, 2024.
• The amendment removes the voting rights previously granted to Series B preferred stockholders, making them non-voting except as required by law.
• Each of the 600 shares of Series B Preferred Stock has a stated value of $10,000.
• The Series B Preferred Stock ranks senior to all other capital stock regarding dividends, distributions, and liquidation payments, unless a majority of Series B holders consent to a higher ranking stock.
• Holders are entitled to cumulative dividends at an annual rate of 8%, increasing to 15% upon a Triggering Event.
• Dividends are payable upon conversion, redemption, or a Bankruptcy Triggering Event.
• The initial conversion price is $3.50 per share of common stock, subject to adjustment if the company sells common stock at a lower price.
• Holders can convert to common stock at an alternate price equal to 80% (or 70% under certain conditions) of the lowest daily volume weighted average price of the common stock during a specified period.
• The company can choose to pay cash equal to 110% of the conversion amount instead of issuing shares at the alternate conversion price.
• The Series B Preferred Stock will automatically convert to common stock 24 months after the initial issuance date.
• Holders can require the company to redeem their shares upon a Triggering Event at a price equal to 110% of the stated value plus accrued dividends.
• The company can also redeem the shares at 110% of the stated value plus accrued dividends at any time.

Sentiment

Score: 6

Explanation: The document is neutral in tone, detailing a change in preferred stock terms. While the removal of voting rights could be seen as negative, the overall terms are within industry standards and do not indicate a significant positive or negative shift.

Positives

• The Series B Preferred Stock maintains its senior ranking for dividends, distributions, and liquidation payments.
• Holders are entitled to cumulative dividends, providing a steady return.
• The alternate conversion price option provides a potential benefit to holders if the stock price declines.
• The company's option to redeem shares at 110% of the stated value provides a potential premium for holders.
• Automatic conversion after 24 months provides a clear exit strategy for holders.

Negatives

• The removal of voting rights reduces the influence of Series B preferred stockholders.
• The conversion price is subject to adjustment, which could dilute the value of the common stock.
• The company has the option to pay cash instead of issuing shares at the alternate conversion price, which could limit potential upside for holders.
• The conversion to common stock is limited to 19.9% of the outstanding common stock unless shareholder approval is obtained.

Risks

• The company's ability to pay dividends and redeem shares is dependent on its financial performance.
• The conversion price is subject to adjustment, which could dilute the value of the common stock.
• The company's ability to issue shares upon conversion is limited by the 19.9% cap unless shareholder approval is obtained.
• Triggering Events could lead to mandatory redemptions, potentially impacting the company's cash flow.
• The company's share price could be negatively impacted by the removal of voting rights for preferred shareholders.

Future Outlook

The document outlines the terms of the Series B Preferred Stock, including conversion and redemption options, but does not provide specific forward-looking statements about the company's future performance or strategy.

Management Comments

• Waqaas Al-Siddiq, Chief Executive Officer of Biotricity Inc., certified the amended certificate of designations.

Industry Context

The amendment of preferred stock terms is a common corporate action, often used to adjust capital structures or investor rights. The removal of voting rights may be a strategic move to consolidate control or simplify decision-making processes.

Comparison to Industry Standards

• The terms of the Series B Preferred Stock, including the dividend rate and conversion options, are within the typical range for preferred stock offerings.
• The removal of voting rights is not uncommon for preferred stock, especially in later-stage financings.
• The 110% redemption premium is a standard feature to compensate investors for early redemption.
• The conversion price and anti-dilution provisions are typical for convertible securities.
• The 19.9% cap on conversion without shareholder approval is a common measure to prevent significant dilution without shareholder consent.

Corporate Governance

Stakeholder Impact

• Shareholders: The removal of voting rights for preferred stockholders may reduce their influence on company decisions.
• Preferred Stockholders: The amendment changes the rights of preferred stockholders, removing voting rights but maintaining other preferences.
• Potential Investors: The terms of the Series B Preferred Stock may influence investment decisions.

Next Steps

• The company may need to seek shareholder approval to issue more than 19.9% of the outstanding common stock upon conversion of the Series B Preferred Stock.
• Holders of the Series B Preferred Stock will need to monitor the company's performance and any Triggering Events that could lead to redemption.

Key Dates

Keywords

Series B Preferred Stock, Convertible Preferred Stock, Voting Rights, Dividends, Conversion Price, Redemption, Biotricity, Capital Stock, Shareholder Approval